AACR: Merck's Keytruda prevents head and neck cancer from returning in industry-first win
Ending a 20-year-plus drought, Merck & Co.’s Keytruda showed that its use around surgery can reduce the risk of certain head and neck cancers from returning. While the drug stands to become a new standard of care, some questions remain.
Ending a 20-year-plus drought, Merck & Co.’s Keytruda showed that its use around surgery can reduce the risk of certain head and neck cancers from returning. While the drug stands to become a new standard of care, some questions remain.
